Такролимус (Tacrolimus)

Tacrolimus (FK-506, fujimycin) blood level testing supports management of immunosuppressive therapy after kidney, liver, heart, and other solid-organ transplantation. By quantifying circulating tacrolimus, the test helps individualize dosing to sustain graft protection while limiting drug-related toxicity. Results are used to evaluate subtherapeutic exposure, suspected nonadherence, overdose, or adverse reactions, and to guide dose or formulation changes at clinician-directed intervals.

Tacrolimus (FK506) is a macrolide immunosuppressant that suppresses T-cell activation and proliferation. It downregulates transcription of immune response genes, reduces T helper–dependent B-cell proliferation, and decreases production of cytokines including interleukin-2, interleukin-3, and interferon-gamma. The drug is widely used to prevent allograft rejection after liver, kidney, heart, and other solid-organ transplants and can substitute for cyclosporine in cases of inadequate response, intolerance, or rejection despite therapy. Compared with cyclosporine, tacrolimus exerts immunosuppressive activity at lower therapeutic doses, but adverse effects such as nephrotoxicity, neurotoxicity, hypertension, and diabetes mellitus may occur. Clinical management is complicated by a narrow therapeutic window, availability of both oral and intravenous routes, interpatient pharmacokinetic and pharmacodynamic variability, and the weak correlation between administered dose and circulating drug concentration. Therapeutic drug monitoring is therefore integral to care, with the timing of the first and subsequent measurements determined by the treating clinician. The average elimination half-life is approximately 10–12 hours, yet a universal therapeutic range is not defined. Target levels depend on the transplanted organ, postoperative course, time since transplantation, individual sensitivity to tacrolimus (including susceptibility to toxic effects), comorbid conditions, age, and race. Absorption and metabolism are influenced by gastrointestinal factors, hepatic and biliary function, and food intake. After liver transplantation and in cholestasis, impaired metabolism and excretion may lead to elevated blood concentrations of tacrolimus and its metabolites. Multiple analytical approaches are used to measure tacrolimus, including enzyme immunoassays, chemiluminescent immunoassays, high-performance liquid chromatography, and mass spectrometry. Each method has distinct characteristics, potential advantages and limitations, and may report in different units; assay systems also vary in diagnostic sensitivity and specificity. For longitudinal care of a given patient, using the same analytical method and reagent system is recommended. Interpretation of results should integrate clinical status and other laboratory or imaging findings rather than relying on drug concentration alone.